The aim of this study was to evaluate the combination of 100 mg of losartan plus 25 mg of hydrochlorothiazide (HCTZ) on a group of twelve moderate to severe untreated non-dipper hypertensive patients.
The benefits of an initial beta-blocker for hypertension in individuals over age 60 are controversial. In the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial, 16,476 hypertensive patients were randomized to verapamil or the physician's choice of atenolol or hydrochlorothiazide (HCTZ), and followed for 3 years. To investigate which baseline characteristics may have influenced the physician's selection of atenolol vs. HCTZ as the control treatment, a multiple logistic regression analysis was performed. The "# of patients" in the table below is the number for whom atenolol was selected by the investigator. Significant predictors (and their Odds Ratios [ORs] , atenolol vs. HCTZ) included: Factors associated with choosing atenolol or HCTZ were generally consistent with current guidelines. Propensity scores derived from this model can be used to "adjust" (in a single step) analyses comparing outcomes between atenolol and HCTZ.
Key Words: Atenolol, Hydrochlorothiazide, Propensity Score Myocardial infarction, sudden cardiac death and stroke all occur more commonly in the morning (6 AM to noon). Diabetic hypertensives have a 2-4 fold higher absolute risk for cardiovascular events, compared to non-diabetics, but often have blunted or reversed circadian variations in pulse rate, blood pressure, and plasma cortisol levels. To compare diabetics and non-diabetics regarding the circadian pattern of cardiovascular events, we examined data from the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial, in which the time of day for cardiovascular events was prospectively recorded.
P-392 CIRCADIAN VARIATION IN CARDIOVASCULAR EVENTS AMONG DIABETICS IN THE CONVINCE TRIAL
After an average of 3 years of follow-up, there were 729 first strokes, myocardial infarctions or cardiovascular deaths; 217 occurred in 3239 diabetics, and 160 of these had the time of day recorded. The distribution of times of events between diabetics and non-diabetics was not significantly different (P ϭ 0.88, chi-square, 3 df). These observations may be confounded by small numbers and poor adherence to initial treatment, but probably not by the initial randomized treatment group. These data suggest that, in CONVINCE, diabetics and non-diabetic hypertensive patients displayed a similar circadian pattern of cardiovascular events. 
